Aliases & Classifications for Tic Disorder

MalaCards integrated aliases for Tic Disorder:

Name: Tic Disorder 12 15 72
Behavioral Tic 72
Tics 6

Classifications:



External Ids:

Disease Ontology 12 DOID:2769
ICD9CM 35 307.2 307.20
MeSH 44 D013981
SNOMED-CT 68 35042001 568005
ICD10 33 F95 F95.9
UMLS 72 C0040188 C0278076

Summaries for Tic Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity.

MalaCards based summary : Tic Disorder, also known as behavioral tic, is related to gilles de la tourette syndrome and oppositional defiant disorder, and has symptoms including ataxia, tremor and myoclonus. An important gene associated with Tic Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Acetylcholine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 75 Tic disorders is defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) based on... more...

Related Diseases for Tic Disorder

Diseases in the Tic Disorder family:

Chronic Tic Disorder Transient Tic Disorder

Diseases related to Tic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 352)
# Related Disease Score Top Affiliating Genes
1 gilles de la tourette syndrome 32.0 SLITRK1 SLC6A3 IMMP2L HDC DRD5 DRD4
2 oppositional defiant disorder 30.4 TPH2 SLC6A3 DRD4 DRD2
3 choreatic disease 30.2 SLC18A2 PNKD
4 conduct disorder 29.9 SLC6A3 DRD5 DRD4 DRD2
5 movement disease 29.9 SLC6A3 SLC18A2 DRD3 DRD2
6 impulse control disorder 29.8 SLITRK1 DRD4 DRD3 DRD2
7 restless legs syndrome 29.6 SLC6A3 DRD3 DRD2
8 dystonia 29.5 SLC6A3 PNKD DRD5 DRD2
9 tardive dyskinesia 29.2 HTR2A DRD3 DRD2
10 early-onset schizophrenia 29.2 HTR2A DRD2 DRD1
11 substance abuse 29.0 SLC6A3 DRD5 DRD4 DRD3 DRD2
12 personality disorder 29.0 SLC6A3 HTR2A DRD4 DRD2
13 migraine with or without aura 1 28.8 HTR2A DRD5 DRD3 DRD2
14 autism spectrum disorder 28.6 TPH2 NRXN1 HTR2A
15 mood disorder 28.5 TPH2 SLC18A2 HTR2A DRD4 DRD3 DRD2
16 obsessive-compulsive disorder 28.4 TPH2 SLITRK1 SLC6A3 HTR2A DRD4 DRD3
17 bipolar disorder 27.9 SLC6A3 SLC18A2 HTR2A DRD3 DRD2
18 disease of mental health 27.6 SLC6A3 NRXN1 HTR2A DRD4 DRD3 DRD2
19 alcohol dependence 27.5 TPH2 SLC6A3 HTR2A DRD4 DRD3 DRD2
20 attention deficit-hyperactivity disorder 27.5 TPH2 SLC6A3 SLC18A2 IMMP2L HTR2A DRD5
21 psychotic disorder 26.2 SLC6A3 SLC18A2 NRXN1 HTR2A DRD4 DRD3
22 schizophrenia 25.4 TPH2 SLC6A3 SLC18A2 NRXN1 HTR2A DRD5
23 chronic tic disorder 12.9
24 transient tic disorder 12.8
25 trigeminal neuralgia 12.2
26 pediatric acute-onset neuropsychiatric syndrome 11.4
27 chorea, benign hereditary 11.2
28 ceroid lipofuscinosis, neuronal, 4b, autosomal dominant 11.1
29 mcleod syndrome 11.1
30 convulsions, familial infantile, with paroxysmal choreoathetosis 11.1
31 cerebral creatine deficiency syndrome 2 11.1
32 adult neuronal ceroid lipofuscinosis 11.1
33 coasy protein-associated neurodegeneration 11.1
34 pediatric autoimmune neuropsychiatric disorders associated with streptococcus infections 11.1
35 cln4 disease 11.1
36 hemifacial spasm, familial 10.5
37 hemifacial spasm 10.5
38 anxiety 10.4
39 headache 10.4
40 heroin dependence 10.3 DRD4 DRD2
41 polysubstance abuse 10.3 DRD3 DRD2
42 facial spasm 10.3
43 delusional disorder 10.3 DRD4 DRD3 DRD2
44 blepharospasm 10.2
45 cluster headache 10.2
46 paroxysmal hemicrania 10.2
47 learning disability 10.2
48 migraine without aura 10.2 DRD4 DRD3 DRD2
49 torticollis 10.2
50 striatal degeneration, autosomal dominant 2 10.2

Graphical network of the top 20 diseases related to Tic Disorder:



Diseases related to Tic Disorder

Symptoms & Phenotypes for Tic Disorder

UMLS symptoms related to Tic Disorder:


ataxia, tremor, myoclonus, dystonia, athetosis, symptoms, synkinesis, recurrent muscle twitches (symptom), tic, motor, tic, gestural, tic, transient, tic, vocal

MGI Mouse Phenotypes related to Tic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 DRD1 DRD2 DRD3 DRD4 DRD5 HDC
2 growth/size/body region MP:0005378 10.06 DRD1 DRD2 DRD3 HDC HSPD1 IMMP2L
3 homeostasis/metabolism MP:0005376 10 DRD1 DRD2 DRD3 DRD4 HDC NRXN1
4 mortality/aging MP:0010768 9.9 DRD1 DRD2 DRD3 DRD5 HSPD1 IMMP2L
5 digestive/alimentary MP:0005381 9.85 DRD1 DRD2 DRD3 HTR2A NRXN1 SLC18A2
6 nervous system MP:0003631 9.77 DRD1 DRD2 DRD3 DRD4 DRD5 HDC
7 taste/olfaction MP:0005394 8.92 DRD2 SLC18A2 SLC6A3 TPH2

Drugs & Therapeutics for Tic Disorder

Drugs for Tic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 208)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Donepezil Approved Phase 4 120014-06-4 3152
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
14
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
15
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
16
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
17
Haloperidol Approved Phase 4 52-86-8 3559
18
Desflurane Approved Phase 4 57041-67-5 42113
19
Ondansetron Approved Phase 4 99614-02-5 4595
20
Galantamine Approved Phase 4 357-70-0 9651
21
Choline Approved, Nutraceutical Phase 4 62-49-7 305
22
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
23
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
24 Antimetabolites Phase 4
25 Liver Extracts Phase 4
26 Lipid Regulating Agents Phase 4
27 Hypolipidemic Agents Phase 4
28 Vasodilator Agents Phase 4
29 Purinergic P2Y Receptor Antagonists Phase 4
30 Purinergic P2 Receptor Antagonists Phase 4
31 Serotonin Receptor Agonists Phase 4
32 Central Nervous System Depressants Phase 4
33 Dopamine Agents Phase 4
34 Antidepressive Agents Phase 4
35 Dopamine Antagonists Phase 4
36 Anti-Bacterial Agents Phase 4
37 Antibiotics, Antitubercular Phase 4
38 Antihypertensive Agents Phase 4
39 Adrenergic alpha-2 Receptor Agonists Phase 4
40 Adrenergic Agonists Phase 4
41 Adrenergic alpha-Agonists Phase 4
42 Adrenergic Agents Phase 4
43 Sympatholytics Phase 4
44 Anticonvulsants Phase 4
45 Neurotransmitter Uptake Inhibitors Phase 4
46 Protective Agents Phase 4
47 Analgesics, Non-Narcotic Phase 4
48 Serotonin Uptake Inhibitors Phase 4
49 Anesthetics Phase 4
50 Anesthetics, General Phase 4

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
2 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
3 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
4 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
5 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
6 Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
7 Guanfacine in Children With Tic Disorders: A Multi-site Study Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
8 A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania Completed NCT00182507 Phase 4 Olanzapine
9 Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial Completed NCT00835159 Phase 4 Rivastigmine Patch
10 Impact of Dexmedetomidine Sedation on the Post-Operative Cognition Dysfunction——a Multiple Center,Randomized, Controlled,Double Blinded Clinical Trial. Completed NCT02275182 Phase 4 Dexmedetomidine;Saline
11 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
12 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
13 Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
14 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
15 The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU Recruiting NCT03931070 Phase 4 Ramelteon;Placebo - Cap
16 Pilot Examination of Galantamine in the Management of Tic Disorders Terminated NCT00226824 Phase 4 galantamine
17 A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Unknown status NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
18 A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
19 A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
20 Behavior Therapy for Children With Chronic Tic Disorders Completed NCT00218777 Phase 2, Phase 3
21 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
22 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
23 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
24 Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD Completed NCT00269815 Phase 3 methylphenidate HCl
25 Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD Completed NCT00269802 Phase 3 OROS methylphenidate HCl;Ritalin;Placebo
26 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286) Completed NCT00206336 Phase 3 Topiramate (drug)
27 Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS Completed NCT00478842 Phase 3
28 Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD Completed NCT00269789 Phase 3 Ritalin;OROS Methylphenidate HCl;Placebo
29 Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD Completed NCT00269776 Phase 3 Placebo;OROS (methylphenidate HCl);Ritalin (methylphenidate)
30 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Safety and Efficacy of Topiramate in the Treatment of Tourette Syndrome (CAPSS-176) Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
31 A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome Recruiting NCT03571256 Phase 3 deutetrabenazine Low;deutetrabenazine High;Placebo
32 A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Recruiting NCT03087201 Phase 3 nabiximols;placebo
33 A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
34 An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
35 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study Unknown status NCT02112253 Phase 1, Phase 2
36 Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS Unknown status NCT01769027 Phase 2 Sertraline+Antibiotic (penicillin/azithromycin);Sertraline+placebo
37 TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest Unknown status NCT02836340 Phase 1, Phase 2 2-Iminobiotin
38 Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
39 Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
40 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
41 Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
42 Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
43 Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
44 A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
45 Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome Completed NCT00004652 Phase 2 pimozide
46 Ecopipam Treatment of Tourette Syndrome Completed NCT01244633 Phase 1, Phase 2 Ecopipam
47 Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy. Completed NCT01446016 Phase 2 Taxane;Docetaxel;Abraxane;Ixabepilone
48 A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome Completed NCT01647269 Phase 2
49 Antibiotic Treatment Trial for the PANDAS/PANS Phenotype Completed NCT01617083 Phase 2 Azithromycin;Placebo
50 Metformin in the Prevention of Alzheimer's Disease Completed NCT00620191 Phase 2 metformin;placebo

Search NIH Clinical Center for Tic Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Clonazepam
Pimozide

Genetic Tests for Tic Disorder

Anatomical Context for Tic Disorder

MalaCards organs/tissues related to Tic Disorder:

41
Brain, Breast, Testes, Liver, Lung, Prostate, Globus Pallidus

Publications for Tic Disorder

Articles related to Tic Disorder:

(show top 50) (show all 4285)
# Title Authors PMID Year
1
Differentiation of Vascular Characteristics Using Contrast-Enhanced Ultrasound Imaging. 38
31208880 2019
2
Inflammation in Tic Disorders and Obsessive-Compulsive Disorder: Are PANS and PANDAS a Path Forward? 38
31111754 2019
3
Associations between autistic-like traits and polymorphisms in NFKBIL1. 38
31162003 2019
4
Chronic Stress, Depression and Personality Type in Patients with Myasthenia Gravis. 38
31408565 2019
5
Pro-inflammatory macrophages promote multiple myeloma resistance to bortezomib therapy. 38
31409628 2019
6
Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. 38
31406992 2019
7
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy. 38
31387918 2019
8
Predictors of therapeutic treatment outcome in adolescent chronic tic disorders. 38
31409430 2019
9
A patient-centered perspective on the future of tic disorder diagnosis: response to "Tic disorders revisited: introduction to the term 'tic spectrum disorders" by Müller-Vahl et al. 38
31375919 2019
10
Metal-Organic Framework-Activated Carbon Composite Materials for the Removal of Ammonia from Contaminated Airstreams. 38
31211486 2019
11
Corrosion behavior of metastable AISI 321 austenitic stainless steel: Investigating the effect of grain size and prior plastic deformation on its degradation pattern in saline media. 38
31431659 2019
12
Voluntary tic suppression and the normalization of motor cortical beta power in Gilles de la Tourette Syndrome: an EEG study. 38
31421054 2019
13
Tics and Tourette Syndrome. 38
31356288 2019
14
Antibodies to neuronal surface proteins in Tourette Syndrome: lack of evidence in a European paediatric cohort. 38
31425826 2019
15
Predictors of the Clinical Course of Tourette Syndrome: A Longitudinal Study. 38
31411102 2019
16
A superior ability to suppress fast inappropriate responses in children with Tourette syndrome is further improved by prospect of reward. 38
31103639 2019
17
The Centrality of Doubting and Checking in the Network Structure of Obsessive-Compulsive Symptom Dimensions in Youth. 38
31421234 2019
18
Tic disorders revisited: introduction of the term "tic spectrum disorders". 38
30661132 2019
19
Aggressive symptoms in children with tic disorders. 38
31396706 2019
20
Maternal thyroid autoimmunity associated with acute-onset neuropsychiatric disorders and global regression in offspring. 38
30720202 2019
21
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update. II. Hyperkinetic disorders. 38
31236685 2019
22
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders. 38
31214855 2019
23
Validation and Normative Data for the Modified Telephone Interview for Cognitive Status: The Sydney Memory and Ageing Study. 38
31290146 2019
24
Validation of neuropsychological tests for the China Health and Retirement Longitudinal Study Harmonized Cognitive Assessment Protocol. 38
31309907 2019
25
Cancer stem cells: A review from origin to therapeutic implications. 38
31286518 2019
26
Work-related stress and incident asthma and rhinitis: results from the SOLAR study. 38
30656403 2019
27
Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition. 38
31257133 2019
28
Evidence-based treatment of Tourette's disorder and chronic tic disorders. 38
31295410 2019
29
Validation of the O3DY French Version (O3DY-F) for the Screening of Cognitive Impairment in Community Seniors in the Emergency Department. 38
31023635 2019
30
Exploring the clinical outcomes after deep brain stimulation in Tourette syndrome. 38
31103958 2019
31
Mobile apps help me manage my tics. 38
31270079 2019
32
Tics in Paroxysmal Kinesigenic Dyskinesia. 38
31392257 2019
33
Reply to: Tics in Paroxysmal Kinesigenic Dyskinesia. 38
31392258 2019
34
Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. 38
31103960 2019
35
Effect of diet, exercise and sleep on tic severity: a scoping review protocol. 38
31289052 2019
36
Population-Based Epidemiology of Pediatric Patients with Treated Tic Disorders from Real-World Evidence in Korea. 38
31361509 2019
37
The Correlation Between the Severity of Premonitory Urges and Tic Symptoms: A Meta-Analysis. 38
31343266 2019
38
Children with Tourette Syndrome in the United States: Parent-Reported Diagnosis, Co-Occurring Disorders, Severity, and Influence of Activities on Tics. 38
31318778 2019
39
Controversies Surrounding the Pathophysiology of Tics. 38
31319731 2019
40
Genetic and environmental contribution to the overlap between ADHD and ASD trait dimensions in young adults: a twin study. 38
30191778 2019
41
Hypoxia- and MicroRNA-Induced Metabolic Reprogramming of Tumor-Initiating Cells. 38
31159361 2019
42
Tic Suppression in Children With Recent-Onset Tics Predicts 1-Year Tic Outcome. 38
31241402 2019
43
circCTIC1 promotes the self-renewal of colon TICs through BPTF-dependent c-Myc expression. 38
30403769 2019
44
An Adult With Obsessive-Compulsive-Related Disorders and Tics Post-Carbon Monoxide Poisoning Who Responded Ultimately to Electroconvulsive Therapy. 38
30633069 2019
45
Marital Status and Dementia: Evidence from the Health and Retirement Study. 38
31251349 2019
46
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts. 38
31259909 2019
47
Targeted resequencing of 358 candidate genes for autism spectrum disorder in a Chinese cohort reveals diagnostic potential and genotype-phenotype correlations. 38
30763456 2019
48
Quality of Life Among Children and Adolescents With Tourette Disorder and Comorbid ADHD: A Clinical Controlled Study. 38
29707998 2019
49
Transcriptomic analysis reveals that BMP4 sensitizes glioblastoma tumor-initiating cells to mechanical cues. 38
31189077 2019
50
The effect of transferrin-targeted, resveratrol-loaded liposomes on neurosphere cultures of glioblastoma: implications for targeting tumour-initiating cells. 38
30475084 2019

Variations for Tic Disorder

ClinVar genetic disease variations for Tic Disorder:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic
2 Translocation Likely pathogenic

Expression for Tic Disorder

Search GEO for disease gene expression data for Tic Disorder.

Pathways for Tic Disorder

Pathways related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 SLC6A3 SLC18A2 DRD5 DRD4 DRD3 DRD2
2
Show member pathways
12.59 DRD5 DRD4 DRD3 DRD2 DRD1
3 12.08 DRD5 DRD4 DRD3 DRD2 DRD1
4
Show member pathways
12 DRD5 DRD4 DRD2 DRD1
5 11.93 TPH2 HTR2A HSPD1
7
Show member pathways
11.8 SLC6A3 SLC18A2 DRD2 DRD1
8 11.77 TPH2 SLC18A2 HTR2A
9 11.71 HTR2A DRD4 DRD3
10
Show member pathways
11.68 SLC18A2 DRD4 DRD3 DRD2
11 11.63 HTR2A DRD2 DRD1
12 11.29 HSPD1 DRD2 DRD1
13
Show member pathways
11.14 HTR2A DRD5 DRD4 DRD3 DRD2 DRD1
14 11.03 SLC6A3 SLC18A2
15 11.03 TPH2 SLC18A2 HTR2A
16 10.6 DRD5 DRD3 DRD2 DRD1

GO Terms for Tic Disorder

Cellular components related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 glutamatergic synapse GO:0098978 9.8 SLITRK1 NRXN1 HTR2A DRD4 DRD3 DRD2
2 endocytic vesicle GO:0030139 9.65 NRXN1 DRD3 DRD2
3 ciliary membrane GO:0060170 9.63 DRD5 DRD2 DRD1
4 integral component of postsynaptic membrane GO:0099055 9.62 SLC6A3 HTR2A DRD2 DRD1
5 non-motile cilium GO:0097730 9.58 DRD5 DRD2 DRD1
6 GABA-ergic synapse GO:0098982 9.55 SLITRK1 NRXN1 DRD3 DRD2 DRD1
7 integral component of presynaptic membrane GO:0099056 9.35 SLC6A3 NRXN1 HTR2A DRD2 DRD1
8 dopaminergic synapse GO:0098691 8.92 SLC6A3 SLC18A2 DRD3 DRD2
9 membrane GO:0016020 10.28 SUSD1 SLITRK1 SLC6A3 SLC18A2 PNKD NRXN1
10 integral component of membrane GO:0016021 10.27 SUSD1 SLITRK1 SLC6A3 SLC18A2 NRXN1 IMMP2L
11 plasma membrane GO:0005886 10.25 SLITRK1 SLC6A3 SLC18A2 NRXN1 HTR2A HSPD1
12 integral component of plasma membrane GO:0005887 10.02 SLC6A3 SLC18A2 NRXN1 HTR2A DRD5 DRD4

Biological processes related to Tic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.99 SLC18A2 NRXN1 HTR2A DRD5 DRD4
2 response to drug GO:0042493 9.93 SLC6A3 HTR2A DRD3 DRD2 DRD1
3 cellular calcium ion homeostasis GO:0006874 9.9 HTR2A DRD5 DRD4 DRD3
4 response to ethanol GO:0045471 9.89 SLC6A3 DRD3 DRD2
5 locomotory behavior GO:0007626 9.88 SLC6A3 SLC18A2 DRD3 DRD2 DRD1
6 synapse assembly GO:0007416 9.87 SLITRK1 NRXN1 DRD2 DRD1
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.85 HTR2A DRD4 DRD1
8 learning GO:0007612 9.84 NRXN1 DRD3 DRD1
9 social behavior GO:0035176 9.83 NRXN1 DRD4 DRD3
10 regulation of synaptic vesicle exocytosis GO:2000300 9.83 HTR2A DRD2 DRD1
11 visual learning GO:0008542 9.83 DRD3 DRD2 DRD1
12 associative learning GO:0008306 9.8 DRD5 DRD2 DRD1
13 adult behavior GO:0030534 9.8 SLITRK1 NRXN1 DRD2
14 negative regulation of blood pressure GO:0045776 9.79 DRD5 DRD3 DRD2
15 arachidonic acid secretion GO:0050482 9.78 DRD4 DRD3 DRD2
16 temperature homeostasis GO:0001659 9.76 HTR2A DRD2 DRD1
17 negative regulation of protein secretion GO:0050709 9.75 DRD4 DRD3 DRD2
18 regulation of presynapse assembly GO:1905606 9.73 SLITRK1 NRXN1
19 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.73 NRXN1 DRD1
20 synaptic membrane adhesion GO:0099560 9.73 SLITRK1 NRXN1
21 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.73 DRD4 DRD3 DRD2
22 synaptic transmission, dopaminergic GO:0001963 9.73 DRD5 DRD3 DRD2 DRD1
23 transmission of nerve impulse GO:0019226 9.72 DRD5 DRD1
24 positive regulation of kinase activity GO:0033674 9.72 HTR2A DRD4
25 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.72 DRD3 DRD2
26 response to iron ion GO:0010039 9.72 SLC6A3 DRD2
27 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.72 DRD5 DRD3 DRD1
28 long-term synaptic depression GO:0060292 9.71 DRD5 DRD1
29 striatum development GO:0021756 9.71 DRD2 DRD1
30 positive regulation of renal sodium excretion GO:0035815 9.71 DRD3 DRD2
31 dopamine receptor signaling pathway GO:0007212 9.71 DRD4 DRD3 DRD2 DRD1
32 grooming behavior GO:0007625 9.7 DRD2 DRD1
33 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.7 DRD4 DRD3
34 G protein-coupled receptor internalization GO:0002031 9.7 DRD3 DRD2
35 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD5 DRD2 DRD1
36 peristalsis GO:0030432 9.69 DRD2 DRD1
37 negative regulation of voltage-gated calcium channel activity GO:1901386 9.69 DRD4 DRD2
38 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.69 HTR2A DRD2
39 dopamine transport GO:0015872 9.69 SLC6A3 SLC18A2 DRD1
40 monoamine transport GO:0015844 9.68 SLC6A3 SLC18A2
41 behavioral response to ethanol GO:0048149 9.68 DRD4 DRD2
42 adenohypophysis development GO:0021984 9.68 SLC6A3 DRD2
43 mating behavior GO:0007617 9.68 DRD5 DRD1
44 cellular response to catecholamine stimulus GO:0071870 9.67 DRD5 DRD1
45 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.67 DRD3 DRD2 DRD1
46 dopamine metabolic process GO:0042417 9.67 DRD4 DRD3 DRD2 DRD1
47 cerebral cortex GABAergic interneuron migration GO:0021853 9.66 DRD2 DRD1
48 negative regulation of dopamine receptor signaling pathway GO:0060160 9.65 DRD3 DRD2
49 behavioral response to cocaine GO:0048148 9.65 HTR2A DRD4 DRD3 DRD2 DRD1
50 regulation of locomotion involved in locomotory behavior GO:0090325 9.64 DRD3 DRD2

Molecular functions related to Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.88 HTR2A DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.55 SLC6A3 HTR2A DRD4 DRD3 DRD2
3 G-protein alpha-subunit binding GO:0001965 9.5 HTR2A DRD5 DRD1
4 adrenergic receptor activity GO:0004935 9.46 DRD3 DRD2
5 monoamine transmembrane transporter activity GO:0008504 9.43 SLC6A3 SLC18A2
6 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
7 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.37 DRD5 DRD1
8 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
9 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Tic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....